• Publications
  • Influence
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
A phase II trial of a combination of intratumoral ONYX-015 injection with cisplatin and 5-fluorouracil in patients with recurrent squamous cell cancer of the head and neck found substantial objective responses, including a high proportion of complete responses. Expand
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology
Consolidation docetaxel after PE/XRT results in increased toxicities but does not further improve survival compared with PE/ XRT alone in patients with stage III inoperable NSCLC. Expand
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.
The first genetically engineered replication-competent virus to demonstrate selective intratumoral replication and necrosis in patients is demonstrated, demonstrating the promise of replication-selective viruses as a novel therapeutic platform against cancer. Expand
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.
ONYX-015 can be safely administered via intratumoral injection to patients with recurrent/refractory SCCHN and evidence of modest antitumoral activity is suggested. Expand
Tamoxifen versus placebo: double-blind adjuvant trial in elderly women with stage II breast cancer.
Significant benefit is seen following tamoxifen in the subsets with 4-10 positive axillary lymph nodes, those who were estrogen receptor positive, or progesterone receptor unknown, and those who had a tumor size less than 3 cm. Expand
A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer.
Intravesical CG0070 was associated with a tolerable safety profile and antibladder cancer activity and patients with borderline or high retinoblastoma phosphorylation who received the multidose schedules had an 81.8% complete response rate. Expand
American Burkitt's lymphoma: a clinicopathologic study of 30 cases. II. Pathologic correlations.
Thirty cases of malignant lymphoma, undifferentiated, Burkitt's type are reviewed. An older median age and a predominance of presentation in abdominal and pelvic sites rather than in the jawExpand
Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo.
Two years of tamoxifen therapy represents an effective postoperative adjuvant treatment for elderly women with stage II breast cancer, resulting in improved time to relapse, statistically fewer distant first recurrences, and minimal toxicity. Expand
A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy
A dose–response relationship was evident forNESP and multiple measures of efficacy, including proportion of patients responding to NESP and the mean change in haemoglobin by week 4 and end of treatment for NESP, and NESP appeared to be well tolerated. Expand
American Burkitt's lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival.
In six cases, the massive tumor regression following chemotherapy was associated with serious metabolid consequences including hyperkalemia, hypocalcemia, hyperphosphatemia and lactic acidosis and there were four sudden deaths in less than 48 hours after chemotherapy. Expand